Skip to content
Back to search

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-10 - Tiotropiumbromid (Spiriva(R) Respimat, ATC: R03BB04)

Techniker KrankenkasseGermanyPublished on Oct 04, 2026
741 days left

Description

The TK aims to conclude discount contracts in accordance with § 130a Abs. 8 SGB V with all suitable pharmaceutical companies for the active substance Tiotropium bromide (Spiriva® Respimat, ATC: R03BB04). The contract will be concluded within the framework of the TK's Open-House-Originals procedure: Individual negotiations on contract terms will not be conducted, and uniform conditions will apply. The TK does not guarantee exclusivity to individual contracting partners. The contract term is a maximum of 24 months, commencing on 01.12.2024. The contract will end no later than 30.11.2026, regardless of the date of contract conclusion. If the patent expires before the aforementioned end date, the contract will automatically terminate at the end of the month of patent expiry. Joining this Open-House-Originals procedure is possible at any time during the contract term. Due to the existence of industrial property rights in relation to the active substance subject to the contract or the active substance combination subject to the procedure, the participation and contract documents will only be made available to pharmaceutical companies that offer or market medicines containing the active substance or active substance combination subject to the procedure or can credibly assure the TK that they will offer or market such medicines during the contract term. All further information can be found in the participation and contract documents. The procedure is extended by 24 months until 30.11.2028.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders